Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Asthma Therapeutics: New Treatment Options And Emerging Drug Discovery Targets

Published by: LeadDiscovery

Published: Apr. 1, 2003



Table of Contents



INTRODUCTION

BACKGROUND INFORMATION

The increasing prevalence of asthma

The role of genetic factors in asthma

The role of infective agents in asthma

Asthma as an inflammatory disease

Airway remodelling

Airway hyperresponsiveness

Anti-inflammatory mechanisms

Transcription factors

MODERN ASTHMA MANAGEMENT

Asthma guidelines

Inhaled corticosteroids

Add-on therapies

Anti-leukotrienes

NEW BRONCHODILATORS

ß2-Agonists.

Drugs which increase cyclic AMP

Drugs which increase cyclic GMP

Selective anticholinergics

K+ channel openers

MEDIATOR ANTAGONISTS

Leukotriene modifiers

Prostaglandin inhibitors

Endothelin antagonists

Antioxidants

Purine receptor modulators

Nitric Oxide

Tryptase inhibitors

CYTOKINES AND CYTOKINE INHIBITORS

Strategies for inhibiting cytokines

Inhibition of Th2 cytokines

Anti-IL-5

Anti-IL-4

Anti-IL-13

Anti-IL-9

Anti-IL-25

Inhibition of proinflammatory cytokines

Anti-inflammatory cytokines

IL-10

Interferons

IL-12

IL-18

CHEMOKINE INHIBITORS

CCR3 inhibitors

inhibitors

Other CCR inhibitors

NEW ANTI-INFLAMMATORY DRUGS

Novel corticosteroids

Soft steroids

Ciclesonide

Dissociated corticosteroids

Phosphodiesterase-4 inhibitors

Transcription factor inhibitors

NF-AT/calcineurin inhibitors

GATA-3 inhibitors

MAP kinase inhibitors

p38 MAP kinase inhibitors

JNK inhibitors

Tyrosine kinase inhibitors

Syk kinase inhibitors

Lyn kinase inhibitors

EGF receptor kinase

Immunomodulators

Th2 cell inhibitors

Cell adhesion blockers

SPECIFIC ANTI-ALLERGIC DRUGS

Cromones

Furosemide

Co-stimulation inhibitors

Anti-IgE

PREVENTIVE STRATEGIES IN ASTHMA

Specific allergen vaccination (immunotherapy)

Peptide immunotherapy

Vaccination

CgP oligonucleotides

GENE THERAPY

Gene transfer

Antisense oligonucleotides

THE ASTHMA THERAPEUTICS MARKET

ASTHMA THERAPEUTICS DEVELOPMENT

Full listing of therapeutics on the market or in developement aranged by originating company, phase of development, pharmacology

Therapeutic profiles of marketed products

zileuton

pseudoephedrine

(R)-salbutamol

bambuterol

formoterol

pirbuterol

reproterol

salbutamol

salmeterol + fluticasone

suplatast tosilate

epinastine

oxatomide

amlexanox

tranilast

Broncostat

Alergim PG

TO-194

pranlukast

montelukast sodium

zafirlukast

cyclidrol

letosteine

flutropium bromide

budilast

aminophylline

doxofylline

theophylline

triamcinolone

beclometasone

budesonide

deflazacort

fluticasone

methylprednisolone

budesonide

beclometasone

budesonide

flunisolide

mometasone

budesonide + formoterol

seratrodast

Therapeutic profiles of products in advanced clinical development

salbutamol

formoterol

omalizumab

ciclesonide

budesonide

flunisolide

israpafant

(R,R)-formoterol

ebastine

roflumilast

CONCLUSIONS & STRATEGIC ADVICE

Abstract

It has proved to be very difficult to develop new classes of anti-asthma therapy, partly because existing drugs, especially inhaled corticosteroids and combination inhalers, are so effective. New classes of therapeutics are expected to allow for oral treatment which will further improve patient compliance and possibly offer improved efficacy to treatment resistant patients. This report evaluates over 30 major therapeutic targets currently under investigation offering an expert view of the potential and the limitations of each target. Such an evaluation is important to the success of drug discovery efforts since the asthma arena is characterized by targets that have initially offered promise but have failed to meet expectations in the clinic.

The only new class of drug developed in the last 30 years are anti-leukotrienes, which are far less effective than inhaled corticosteroids. New bronchodilators have been difficult to develop as new drugs are less effective than b2-agonists and have more side effects. Mediator antagonists have proved disappointing as so many mediators are involved in asthma.

A number of emerging targets are however especially promising including IL-13, TACE inhibitors, IL-10, dissociated steroids, PDE4, IgE and vaccine therapies. Proof of concept data and expert opinion on each of these targets is offered in this report. Over 30 other targets are also discussed even though they have yet to be adequately investigated. For each of these, available data is provided and the risks associated with these targets are analyzed in order to guide future research.

The report concludes with a listing of therapeutics on the market or in development. Profiles are provided for those in advanced development or those that have been launched; a strategic analysis is then provided underlining those targets perceived to be the most promising and how these targets should be exploited.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options

See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009